Sotatercept improved walking distance in pulmonary arterial hypertension trials
Compared with placebo, patients receiving sotatercept walked farther in a timed test. Mortality differences were statistically inconclusive, and the review reported adverse events.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
In patients with pulmonary arterial hypertension, sotatercept improved walking-test distance compared with placebo and improved other functional and pressure measurements. The pooled trials did not show statistically clear differences in deaths from any cause or in a laboratory marker called NT-proBNP. Adverse events were reported, and sustained benefits remain uncertain.
The abstract does not provide trial durations, absolute adverse-event frequencies or mortality estimates. The authors call for longer studies to determine whether the reported benefits persist.
The walking result had a measurable distance
For the 6-minute walking test, the pooled mean difference favored sotatercept by 40.57 m over placebo, with a 95% confidence interval of 26.64 to 54.5 m. The abstract does not specify when this test was assessed.
Functional changes came with safety questions
The review also reported improved functional classification and lower lung-vessel resistance and artery pressure. Reported adverse events included nosebleeds, increased hemoglobin and telangiectasia, meaning visibly enlarged small blood vessels. Their frequencies were not supplied in the abstract.
The original publication
Efficacy and safety of sotatercept in pulmonary arterial hypertension: a meta-analysis of randomized controlled trials.
Ershed M, da Silva ABN, Felix de Farias Dos Santos AC et al.
Expert Rev Respir Med · 2025
- PubMed ID
- 40611681
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.